Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›EMEND 125 mg hard capsules EMEND 80 mg hard capsules
Medicines register · Ireland

EMEND 125 mg hard capsules EMEND 80 mg hard capsules

Authorisation EU/1/03/262/006 · Merck Sharp & Dohme BV,

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Merck Sharp & Dohme BV, (all products →)
Active substance
Aprepitant
Clinical trials
5 clinical trials →
Dosage form
Capsule, hard
ATC code
A04AD12
First authorised
11/11/2003
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
New active substance (Article 8(3) of Directive No 2001/83/EC)

Aprepitant: supply and approvals

8 authorised products on the HPRA list contain Aprepitant. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
Aprepitant Oral Powder for Suspension: resolved, updated 8 Apr 2026
Germany (BfArM)
6 supply notices, e.g. Aprepitant Zentiva 80 mg und 125 mg Hartkapseln (1 Oct 2025 to 30 Apr 2027)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 262. It has been authorised for 23 years (since 11 November 2003). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Aprepitant in Ireland

7 other products on the HPRA list contain Aprepitant, from 2 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Aprepitant Accord 125 mg hard capsulesAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Aprepitant Accord 125 mg/80 mg hard capsulesAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Aprepitant Accord 125 mg/80 mg hard capsulesAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Aprepitant Accord 80 mg hard capsulesAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
EMEND 125 mg hard capsulesMerck Sharp & Dohme BV,Centralised EU authorisationNot stated
EMEND 80 mg hard capsulesMerck Sharp & Dohme BV,Centralised EU authorisationNot stated
Emend 125 mg powder for oral suspensionMerck Sharp & Dohme BV,Centralised EU authorisationNot stated

The licence holder

Merck Sharp & Dohme BV, holds 71 products on the HPRA list, with 90 different active substances; 1 of the products is marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.